<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Dipna Pharmachem Ltd. (DPL) — Tipsheet</title>
    <link>https://tipsheet.markets/company/dpl/</link>
    <atom:link href="https://tipsheet.markets/company/dpl/feed.xml" rel="self" type="application/rss+xml" />
    <description>Every Tipsheet Editorial note covering Dipna Pharmachem Ltd. (DPL), newest first. Grounded in BSE/NSE primary-source filings.</description>
    <language>en-in</language>
    <lastBuildDate>Mon, 06 Jul 2026 10:22:47 GMT</lastBuildDate>
    <item>
      <title>Dipna Pharmachem net profit jumps to ₹2.63 cr, steel segment drives earnings</title>
      <link>https://tipsheet.markets/dpl-dipna-pharmachem-net-profit-jumps-to-2-63-cr-steel-segment-drives-earnings-118632/</link>
      <guid isPermaLink="true">https://tipsheet.markets/dpl-dipna-pharmachem-net-profit-jumps-to-2-63-cr-steel-segment-drives-earnings-118632/</guid>
      <pubDate>Thu, 02 Jul 2026 21:24:15 GMT</pubDate>
      <description>FY26 profit rises from ₹97.40 lakh; steel segment profit surges to ₹866.83 lakh. First-time Ind AS adoption, unmodified audit opinion. Routine filing, no new catalysts.</description>
      <content:encoded><![CDATA[<p><em>FY26 profit rises from ₹97.40 lakh; steel segment profit surges to ₹866.83 lakh. First-time Ind AS adoption, unmodified audit opinion. Routine filing, no new catalysts.</em></p>
<h3>What’s new</h3><ul><li>Net profit rose to ₹2.63 cr from ₹97.40 lakh.</li><li>Steel segment profit jumped to ₹866.83 lakh from ₹17.72 lakh; chemicals division posted a loss.</li><li>Auditor gave unmodified opinion; no deviation in preferential issue fund utilisation.</li></ul>
<h3>Why it matters</h3><p>For a ₹19 cr market-cap company, the profit increase is notable, but it's entirely driven by the steel segment. The chemicals division remains a drag. The filing is routine regulatory disclosure, already priced in.</p>
<h3>What we’re watching</h3><ul><li>Sustainability of steel segment profitability in FY27.</li><li>Chemicals division turnaround or continued losses.</li><li>Impact of first-time Ind AS adoption on comparability.</li></ul>
<h3>The full read</h3><p>Dipna Pharmachem's FY26 net profit rose to <strong>₹2.63 crore</strong> from <strong>₹97.40 lakh</strong> on total income of <strong>₹129.09 crore</strong>. That looks strong for a <strong>₹19 crore</strong> market-cap company. But the steel segment alone delivered <strong>₹866.83 lakh</strong> in profit, up from <strong>₹17.72 lakh</strong>. Hardly a diversified story. Meanwhile, the chemicals division lost money – a drag that persists. This is a routine annual filing with an unmodified audit opinion and no deviation in preferential issue proceeds. The first-time adoption of Ind AS adds accounting noise. One segment doing the heavy lifting makes this result more fragile than the headline suggests, and investors should watch whether steel profitability is sustainable into FY27.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=543594&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=DPL">NSE</a></p>]]></content:encoded>
      <category>Earnings</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
  </channel>
</rss>